199 related articles for article (PubMed ID: 22931656)
1. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
Li J; Wu XB; Zhou Y; Wang X; Chen JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
5. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
6. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
8. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
9. The Role of
Deng S; Zhang B; Zhou Y; Xu X; Li J; Sang S; Zhang W
Contrast Media Mol Imaging; 2018; 2018():4198673. PubMed ID: 30154686
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of multiple myeloma: a report of 182 cases].
Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
Hsiao LT; Yang CF; Yang SH; Gau JP; Yu YB; Hong YC; Liu CY; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
[TBL] [Abstract][Full Text] [Related]
13. [Classification, staging and prognostic indices for multiple myeloma].
Hotta T
Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?
Baur A; Stäbler A; Nagel D; Lamerz R; Bartl R; Hiller E; Wendtner C; Bachner F; Reiser M
Cancer; 2002 Sep; 95(6):1334-45. PubMed ID: 12216103
[TBL] [Abstract][Full Text] [Related]
15. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.
Shimamoto Y
Cancer Detect Prev; 1995; 19(5):426-35. PubMed ID: 7585729
[TBL] [Abstract][Full Text] [Related]
16. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and survival of Chilean patients with multiple myeloma].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2007 Sep; 135(9):1111-7. PubMed ID: 18064364
[TBL] [Abstract][Full Text] [Related]
18. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?
Filonzi G; Mancuso K; Zamagni E; Nanni C; Spinnato P; Cavo M; Fanti S; Salizzoni E; Bazzocchi A
AJR Am J Roentgenol; 2017 Jul; 209(1):152-158. PubMed ID: 28418695
[TBL] [Abstract][Full Text] [Related]
20. DNA-image cytometry and clinical staging systems in multiple myeloma.
Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
